3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphatic Metastasis
1
Interventions
Docetaxel
33
Prednisone
28
enzalutamide
19
Abiraterone Acetate
13
pembrolizumab
11
gallium 68 PSMA-11
9
Leuprolide
9
Radiotherapy
8
Pluvicto
8
Magnetic Resonance Spectroscopy
8
Nivolumab
7
Estramustine
7
abiraterone
6
Radiotherapy, Intensity-Modulated
6
Goserelin
6
Carboplatin
6
Biopsy
6
olaparib
5
cemiplimab
5
bicalutamide
5
Specimen Handling
5
Paclitaxel
5
Cyclophosphamide
5
temsirolimus
4
orteronel
4
darolutamide
4
cabazitaxel
4
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
4
Sirolimus
4
Radiosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Prostatic Neoplasms
×
PITX2 protein, human
×
Clear all
NCT04300673
2022-04-29
DETECT
Radboud University Medical Center
Phase 1/2
Unknown
20 enrolled